Safety pharmacology seeks to predict if a drug administered to humans would be unsafe. Prior to 1990, companies conducted toxicological testing during drug discovery. In the 1990s, the antihistamine terfenadine was withdrawn due to its potential for life-threatening cardiac side effects. This led to increased efforts by industry and regulators through initiatives like the International Conference on Harmonisation to improve safety testing and accommodate regulatory requirements. Safety pharmacology testing helps determine potential undesirable effects on body systems and inform decisions on advancing to human testing or discontinuing development, with the goal of identifying unsafe drugs early.